U.S. authorities launched a fact‑finding probe into Chinese state support and pricing practices in the biotech sector, initiating investigations by the International Trade Commission. The inquiries will collect evidence on whether government subsidies and market conduct in China have disadvantaged U.S. biotech firms and could set the stage for tariffs or trade restrictions. The move follows growing political scrutiny of strategic tech sectors; U.S. and Western investors have already increased due diligence on China partnerships. Companies with cross‑border manufacturing or supply chains should expect elevated regulatory and commercial risk.